The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy

Area of Science:

• Oncology
• Pharmacology
• Cancer Biology

Background:

• Drug resistance to vascular endothelial growth factor (VEGF) pathway inhibitors poses a significant clinical challenge.
• VEGF pathway inhibitors are crucial in targeting tumor angiogenesis, but treatment failure is common.
• Understanding the mechanisms of resistance is vital for developing alternative or combination therapies.

Purpose of the Study:

• To review and analyze preclinical methodologies used to study resistance to VEGF pathway inhibitors.
• To identify inconsistencies and limitations in current preclinical models for assessing antiangiogenic treatment failure.
• To highlight the need for improved preclinical methods that better predict clinical outcomes.

Main Methods:

• A literature search was conducted to identify studies examining resistance to VEGF pathway inhibitors.
• 109 papers focusing on treatment failure as a starting point for mechanistic studies were identified.
• The methodologies used in these preclinical studies were analyzed for their definitions, reagents, and experimental approaches.

Main Results:

• Definitions of drug resistance in preclinical studies are broad and inconsistent.
• A limited number of reagents are used across studies, and methodologies often lack clinical relevance.
• Preclinical models frequently fail to represent clinically relevant disease stages or progression.

Conclusions:

• Current preclinical methodologies for studying resistance to VEGF inhibitors are diverse and inconsistently applied.
• There is a critical need for standardized and clinically relevant preclinical models to study resistance mechanisms.
• Improved methodologies are essential for predicting and overcoming treatment failure in patients receiving antiangiogenic therapies.